NEW YORK (GenomeWeb News) – Exact Sciences said Tuesday that it has licensed worldwide rights to Hologic's Invader plus and real-time Invader detection chemistries for colorectal screening applications.

Terms of the agreement are not being disclosed by the firms.

The Invader chemistry was developed by Hologic subsidiary Third Wave Technologies, which formerly was run by Exact Sciences' current President and CEO Kevin Conroy, before it was acquired by Hologic for $580 million in July 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.